News
ZNTL
--
0.00%
--
BRIEF-Zentalis Pharmaceuticals And Tempus Announce Strategic Collaboration To Advance Research And Development Capabilities
reuters.com · 02/25 13:35
BRIEF-Zentalis Pharmaceuticals And Tempus Announce Strategic Collaboration
reuters.com · 02/25 12:37
Zentalis and Tempus ink research collaboration deal
Zentalis Pharmaceuticals (ZNTL) inks strategic collaboration with Tempus (TMPHF) to leverage the company’s patient-derived organoid biological modeling platform to strengthen Zentalis’ discovery and research capabilities.Tempus’ proprietary platform has th...
Seekingalpha · 02/25 12:26
Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced a strategic collaboration with Tempus to leverage the company's patient-derived organoid biological modeling platform to strengthen Zentalis' discovery and research capabilities.
GlobeNewswire · 02/25 12:04
Zentalis Pharmaceuticals Says To Present Initial Clinical Data On ZN-c3 At AACR Annual Meeting 2021
Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021 NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage
Benzinga · 02/24 12:03
Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways ...
GlobeNewswire · 02/24 12:00
Zentalis Pharmaceuticals Names Enoch Kariuki to Bd of Directors
Zentalis Pharmaceuticals Names Enoch Kariuki to Bd of Directors
Dow Jones · 02/10 12:05
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
NEW YORK & SAN DIEGO, Feb 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc....
GlobeNewswire · 02/10 12:00
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc....
GlobeNewswire · 02/05 12:00
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways ...
GlobeNewswire · 02/05 12:00
Why Earnings Season Could Be Great for Zentalis (ZNTL)
Zacks.com · 02/04 16:02
Why Earnings Season Could Be Great for Zentalis (ZNTL)
Zacks.com · 02/04 13:41
Why Earnings Season Could Be Great for Zentalis (ZNTL)
Zentalis (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 02/04 13:41
DJ Zentalis Pharmaceuticals Price Target Announced at $65.00/Share by Wedbush
Dow Jones · 01/20 10:41
DJ Zentalis Pharmaceuticals Initiated at Outperform by Wedbush
Dow Jones · 01/20 10:41
Analyst Actions: Wedbush Starts Zentalis Pharmaceuticals at Outperform With $65 Price Target
MT Newswires · 01/20 06:59
Zentalis initiates multiple early-stage clinical trials for cancer
The clinical-stage biopharma, Zentalis Pharmaceuticals (ZNTL) announces that it has started the patient dosing in two combination trials and one monotherapy clinical trial in the Phase 1 stage as mentioned
Seekingalpha · 01/06 12:38
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
GlobeNewswire · 01/06 12:00
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
Advancing the development of its oral SERD, WEE1 inhibitor and BCL-2 inhibitor product candidatesNEW YORK and SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on ...
GlobeNewswire · 01/06 12:00
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
GlobeNewswire · 01/06 12:00
Webull provides a variety of real-time ZNTL stock news. You can receive the latest news about Zentalis Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZNTL
Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.